medi4276
mAbexperimentalADC
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 23, 2015 (NCT02576548)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- Tubulysin
Oral
No
Parenteral
No
Topical
No
Also known as
- medi4276
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02576548 | Phase 1/Phase 2 (Phase 2) | Sep 23, 2015 | MedImmune, Sponsor GmbH |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedImmune | For profit | 1 | 1 | 1 | 2015 |
| Sponsor GmbH | Academic/Hospital | 1 | 0 | 1 | 2015 |
2 organizations
Page 1 / 1